LEXARIA BIOSCIENCE CORP. Accounts Receivable, before Allowance for Credit Loss
LEXARIA BIOSCIENCE CORP. (LEXX) had Accounts Receivable, before Allowance for Credit Loss of $272.02 thousand as of 2024-05-31, per its 10-Q filed 2024-07-12.
Discontinued › Balance Sheet › Assets
us-gaap:AccountsReceivableGross · last filed 2024-07-12
- 2024-05-31: Accounts Receivable, before Allowance for Credit Loss $272.02K.
- 2024-02-29: Accounts Receivable, before Allowance for Credit Loss $396.58K.
- 2023-11-30: Accounts Receivable, before Allowance for Credit Loss $583.29K.
- 2023-08-31: Accounts Receivable, before Allowance for Credit Loss $175.25K.
| Period end | Accounts Receivable, before Allowance for Credit Loss |
|---|---|
| 2024-05-31 | $272.02K 10-Q · filed 2024-07-12 |
| 2024-02-29 | $396.58K 10-Q · filed 2024-04-09 |
| 2023-11-30 | $583.29K 10-Q · filed 2024-01-12 |
| 2023-08-31 | $175.25K 10-Q · filed 2024-07-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |